The possible involvement of sema3A and sema4A in the pathogenesis of multiple sclerosis

Immune semaphorins are widely accepted to have functional impact on autoimmune diseases. To assess the status of sema3A and sema4A in the pathogenesis of Multiple Sclerosis (MS). Sema3A expression on (T regulatory cells)Tregs was decreased in MS patients, compared to healthy controls (35.85 ± 16.7%...

Full description

Saved in:
Bibliographic Details
Published in:Clinical immunology (Orlando, Fla.) Fla.), 2022-05, Vol.238, p.109017-109017, Article 109017
Main Authors: Eiza, N., Garty, M., Staun-Ram, E., Miller, A., Vadasz, Z.
Format: Article
Language:English
Subjects:
Autoimmunity
Humans
Multiple Sclerosis
Semaphorin-3A
Semaphorins
Severity of Illness Index
T cells
T-Lymphocytes, Regulatory - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune semaphorins are widely accepted to have functional impact on autoimmune diseases. To assess the status of sema3A and sema4A in the pathogenesis of Multiple Sclerosis (MS). Sema3A expression on (T regulatory cells)Tregs was decreased in MS patients, compared to healthy controls (35.85 ± 16.7% vs 88.27 ± 3.8%; p ≤ 0.001). Serum levels of sema3A were decreased in MS patients 2.95 ± 0.43 vs 18.67 ± 5.7 ng/ml in healthy individuals; p ≤ 0.001. Sema4A serum levels were increased in MS patients compared to healthy individuals (12.99 ± 8.6 vs 5.83 ± 3.91 ng/ml; p ≤ 0.001). Sema3A and sema4A serum levels were found to be in negative/positive correlation with MS disease severity (rs = 0.62, rs = −0.49, respectively). We show that sema3A is a regulatory molecule in MS, whereas sema4A is a stimulatory one. Targeting sema3A and sema4A could become a potential therapeutic approach in MS.
ISSN:1521-6616
1521-7035
DOI:10.1016/j.clim.2022.109017